Age Over 80 and Prostate Cancer


New Evidence Challenges "Too Old to Treat" Assumptions

Recent research reveals elderly men with prostate cancer benefit significantly from active treatment—plus critical insights on sarcopenia, frailty assessment, and maintaining quality of life

FOR IMMEDIATE RELEASE
Informed Prostate Cancer Support Group Newsletter

Groundbreaking research is overturning long-held assumptions about treating prostate cancer in men over 80, revealing that definitive therapy significantly improves survival while managing age-related health challenges becomes increasingly important for treatment success.

Definitive Treatment Shows 50% Mortality Reduction

A landmark analysis of nearly 20,000 men aged 80 or older with high-risk prostate cancer found that definitive local therapy—including surgery or radiation therapy with or without androgen deprivation therapy (ADT)—is associated with a 50% reduction in overall mortality compared with observation or ADT alone.

The study recommends that life expectancy (physiologic age) be taken into account over chronological age, and that elderly men with good life expectancy (greater than 5 years and minimal comorbidity) should be offered definitive, life-prolonging therapy.

Recent 2025 data from the SEER-17 database examining over 53,000 patients aged 80 and older found that only 1.4% underwent radical prostatectomy, while 68.2% received non-definitive therapy. This suggests many elderly patients may be undertreated based solely on age rather than health status.

The Sarcopenia Challenge: Muscle Loss During Treatment

One of the most significant yet under-recognized challenges facing elderly prostate cancer patients is sarcopenia—the age-related loss of muscle mass and strength that accelerates during treatment.

A systematic review found that sarcopenia affects approximately 44% of prostate cancer patients overall, with rates potentially higher (54.6%) in metastatic disease compared to early disease (31.8%).

Critical Finding for ADT Patients:
Men receiving androgen deprivation therapy experience significant lean body mass declines, with older men experiencing greater muscle loss than younger patients. Research shows that muscle loss of 5% or more within one year of starting ADT is associated with increased non-cancer mortality in high-risk prostate cancer patients.

In men with metastatic castration-resistant prostate cancer, sarcopenia is associated with higher rates of severe treatment toxicity, emergency room visits, disease progression, and overall mortality.

Frailty Assessment: The Missing Piece in Treatment Planning

A 2025 study found that comprehensive geriatric assessment (CGA) changed treatment decisions in 40.7% of elderly prostate cancer patients, with the assessment revealing that over 90% had indications for geriatric evaluation despite initial assumptions of fitness.

Among older men with metastatic castration-resistant prostate cancer, 37% were pre-frail and 17% were frail, with frailty associated with worse quality of life, higher pain, and greater fatigue.

The study showed that 63.6% of patients had WHO performance status greater than 1, and 86.4% had at least one competing comorbidity, highlighting the complexity of treatment decisions in this population.

What Prostate Cancer Patients Over 80 Should Know

1. Age Alone Should Not Disqualify You From Treatment For men aged 80-85 with low comorbidity scores, definitive local therapy may provide significant survival benefits and should be discussed with healthcare providers.

2. Radiation Therapy Remains Highly Effective A study of 88 patients aged 75 and older treated with intensity-modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) achieved 5-year and 7-year overall survival rates of 87.9% and 80.2% respectively, with only 1.3-3.5% experiencing grade 3 or higher toxicities.

3. Combat Muscle Loss Proactively In patients with metastatic prostate cancer receiving ADT, combined resistance and aerobic exercise programs helped combat and reverse muscle loss. Resistance training is superior to aerobic training in reversing both sarcopenia and muscle weakness.

4. Request a Comprehensive Geriatric Assessment Geriatric assessments evaluate physical performance, functional status, comorbidities, medications, nutrition, cognition, social support, and psychological status to provide evidence-based recommendations for adjusting care.

5. Monitor For Treatment-Related Complications Studies show high prevalence of muscle disorders before ADT initiation and increased fall risk at the end of ADT, highlighting the importance of screening for sarcopenia before treatment begins.

The Bottom Line

The evidence is clear: chronological age alone should not determine prostate cancer treatment decisions. Men over 80 with good functional status and limited comorbidities can benefit substantially from definitive therapy. However, success requires:

  • Comprehensive geriatric assessment before treatment decisions
  • Proactive management of sarcopenia through exercise and nutrition
  • Regular monitoring of muscle mass and physical function
  • Individualized treatment plans based on physiologic rather than chronologic age

Advocacy Point: If your oncologist suggests observation based primarily on your age, ask about a formal geriatric assessment and request data on how your individual health status compares to patients who benefited from treatment in recent studies.

SOURCES AND CITATIONS

  1. Fischer-Valuck, B.W., et al. (2022). "Treatment Patterns and Overall Survival Outcomes Among Patients Aged 80 yr or Older with High-risk Prostate Cancer." European Urology Open Science, 37, 80-89.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883189/

  2. Kim, I.E., Jr., et al. (2025). "Radical prostatectomy is associated with favorable outcomes in patients over 80 years old." American Journal of Clinical and Experimental Urology, 13(1), 33-42.
    https://pubmed.ncbi.nlm.nih.gov/40124572/

  3. Nakamura, M., et al. (2022). "Long-term Outcomes of Radiation Therapy for Prostate Cancer in Elderly Patients Aged ≥75 Years." Anticancer Research, 42(7), 3529-3536.
    https://ar.iiarjournals.org/content/42/7/3529

  4. Bozzetti, F., et al. (2023). "The trajectory of sarcopenia following diagnosis of prostate cancer: A systematic review and meta-analysis." Journal of Geriatric Oncology, 14(6).
    https://www.geriatriconcology.net/article/S1879-4068(23)00191-1/fulltext

  5. Smith, M.R., et al. (2012). "Sarcopenia During Androgen-Deprivation Therapy for Prostate Cancer." Journal of Clinical Oncology, 30(26), 3271-3276.
    https://ascopubs.org/doi/10.1200/JCO.2011.38.8850

  6. Zhang, P., et al. (2021). "Muscle Loss During Androgen Deprivation Therapy Is Associated With Higher Risk of Non-Cancer Mortality in High-Risk Prostate Cancer." Frontiers in Oncology, 11.
    https://pmc.ncbi.nlm.nih.gov/articles/PMC8485032/

  7. Loh, K.P., et al. (2023). "The impact of sarcopenia on clinical outcomes in men with metastatic castrate-resistant prostate cancer." PLOS ONE, 18(5).
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234556/

  8. Bonneau, M., et al. (2025). "Impact of comprehensive geriatric assessment on treatment decisions in older prostate cancer patients." BMC Cancer, 25, 642.
    https://bmccancer.biomedcentral.com/articles/10.1186/s12885-025-13961-z

  9. Kim, J.W., et al. (2023). "The role of frailty in modifying physical function and quality of life over time in older men with metastatic castration-resistant prostate cancer." Journal of Geriatric Oncology, 14(1).
    https://www.sciencedirect.com/science/article/abs/pii/S187940682200546X

  10. Williams, G.R., et al. (2021). "Sarcopenia in the Older Adult With Cancer." Journal of Clinical Oncology, 39(19), 2068-2083.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260902/

  11. Bonneau, C., et al. (2020). "HoSAGE: Sarcopenia in Older Patients before and after Treatment with Androgen Deprivation Therapy and Radiotherapy for Prostate Cancer." Journal of Nutrition, Health & Aging, 24, 205-209.
    https://pubmed.ncbi.nlm.nih.gov/32003412/

  12. Cancer Today Magazine (December 2024). "Cancer Care for Older Adults: Geriatric assessments can help physicians and older patients choose effective treatments with fewer side effects."
    https://www.cancertodaymag.org/winter-2024-2025/cancer-care-for-older-adults/

  13. Droz, J.P., et al. (2019). "Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients." European Journal of Cancer, 116, 116-136.
    https://pubmed.ncbi.nlm.nih.gov/31195356/

For More Information:
Contact your IPCSG chapter leader or visit www.ipcsg.org for support group meetings and educational resources.

This article is for informational purposes only and should not replace consultation with your healthcare team.

 

Comments

Post a Comment

Popular posts from this blog

A 10-Second Steam Blast: The New Weapon Against Prostate Cancer?

Image
Vanquish® Water Vapor Ablation System, Francis Medical Steams Out Prostate Cancer The Vanquish® Water Vapor Ablation System, developed by Francis Medical, Inc. , represents an innovative approach to treating prostate cancer using water vapor (steam) to ablate cancerous tissue. This minimally invasive technique aims to target and destroy prostate cancer cells while minimizing damage to surrounding healthy tissue, potentially reducing common side effects associated with traditional treatments like surgery and radiation, Mechanism of Action:  The Vanquish system utilizes the thermal energy stored in sterile water vapor to ablate cancerous prostate tissue. During the procedure, a catheter is inserted through the urethra into the prostate, delivering water vapor directly to the targeted tissue. As the vapor condenses back into liquid, it releases stored thermal energy, effectively destroying the cancerous cells. This method is designed to respect the prostate's natural boundaries, ...
Read more

Dr. Christopher Kane of UCSD Health Appointed Chairman of the American Board of Urology

Image
  Dr. Christopher Kane of UCSD Health Appointed Chairman of the American Board of Urology SAN DIEGO, May 21, 2025 - Dr. Christopher Kane, a distinguished urologist and Professor of Urology at UC San Diego Health, has been appointed Chairman of the American Board of Urology (ABU), the organization announced today. Dr. Kane, who has served as CEO of UC San Diego Health Physician Group and Dean of Clinical Affairs at the UC San Diego School of Medicine, brings decades of experience in urologic oncology and leadership to this prestigious national position. Extensive Academic and Research Background Dr. Kane earned his medical degree from Uniformed Services University in Bethesda, Maryland, followed by a residency in urology at the Naval Medical Center San Diego and a fellowship in urologic oncology at the National Cancer Institute. He joined the UCSD faculty in 2007 after serving as a Navy physician for 12 years. As the C. Lowell and JoEllen Parsons Endowed Chair in Urology, Dr. ...
Read more

PSMA-Targeted Therapies for Prostate Cancer: Move Treatment Earlier in Disease Course

Image
  Interactive Graphic PSMA-Targeted Therapies for Prostate Cancer: Move Treatment Earlier in Disease Course Landmark FDA approval expands access to radioligand therapy while new research explores next-generation treatments By [Your Name] for the IPCSG Newsletter The landscape of prostate cancer treatment has undergone a seismic shift in recent months, with groundbreaking advances in prostate-specific membrane antigen (PSMA)-targeted therapies offering new hope to patients across different stages of the disease. Most significantly, the FDA's March 2025 expansion of Pluvicto (lutetium-177-PSMA-617) approval now allows treatment before chemotherapy, potentially tripling the number of eligible patients. Major FDA Approval Expands Treatment Access On March 28, 2025, the FDA approved a crucial expansion of Pluvicto's indication, allowing its use in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen recepto...
Read more